What is a major complication associated with thrombolytic therapy?

What is a major complication associated with thrombolytic therapy?

• A. Bleeding
• B. Hypertension
• C. Hypoglycemia
• D. Hyperkalemia

Answer: (A)

Bleeding is the major complication of thrombolytic therapy. These drugs work by activating plasmin to break down fibrin clots, but they also impair clotting factors in the bloodstream. That systemic fibrinolysis can lead to serious hemorrhage, including intracranial bleeding, which is life-threatening. Because of this risk, patients are carefully selected for therapy and are monitored closely for signs of bleeding—such as oozing from IV sites, gum or nasal bleeding, hematemesis or melena, and sudden changes in neurologic status. While blood pressure changes or electrolyte disturbances can occur in hospitalized patients, they are not the primary risks tied specifically to thrombolytics; the key concern is unchecked bleeding.

Bleeding is the major complication of thrombolytic therapy. These drugs work by activating plasmin to break down fibrin clots, but they also impair clotting factors in the bloodstream. That systemic fibrinolysis can lead to serious hemorrhage, including intracranial bleeding, which is life-threatening. Because of this risk, patients are carefully selected for therapy and are monitored closely for signs of bleeding—such as oozing from IV sites, gum or nasal bleeding, hematemesis or melena, and sudden changes in neurologic status. While blood pressure changes or electrolyte disturbances can occur in hospitalized patients, they are not the primary risks tied specifically to thrombolytics; the key concern is unchecked bleeding.